- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04684719
Type O volbloed en beoordeling van leeftijd tijdens preklinische reanimatieproef (TOWAR)
Type O volbloed en beoordeling van leeftijd tijdens prehospitale reanimatie (TOWAR)-onderzoek
Open label, multi-center, pre-hospital randomized trial utilizing 10 level-1 trauma centers designed to determine the efficacy and safety of low titer whole blood resuscitation as compared to component blood resuscitation in patients at risk of hemorrhagic shock and to appropriately characterize the hemostatic competency of whole blood relative to its age.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35294
- University of Alabama at Birmingham
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40292
- University of Louisville
-
-
Mississippi
-
Jackson, Mississippi, Verenigde Staten, 39216
- University of Mississippi Medical Center (UMMC)
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45267
- University of Cincinatti
-
Cleveland, Ohio, Verenigde Staten, 44109
- Metrohealth Systems
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213
- University of Pittsburgh
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37920
- University of Tennessee Medical Center
-
Nashville, Tennessee, Verenigde Staten, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- University of Texas Health Science Center at Houston
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98104
- University of Washington
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
1.) Injured patients at risk of hemorrhagic shock being transported from scene or referral hospital to a participating TOWAR trial site that meet requirements for initiation of blood or blood component transfusion
AND
2A.) Systolic blood pressure ≤ 90mmHg and tachycardia (HR ≥ 108) at scene, at outside hospital or during transport OR
2B.) Systolic blood pressure ≤ 70mmHg at scene, at outside hospital or during transport
Exclusion Criteria:
- Wearing NO TOWAR opt-out bracelet
- Age > 90 or < 18 years of age
- Isolated fall from standing injury mechanism
- Known prisoner or known pregnancy
- Traumatic arrest with > 5 minutes of CPR without return of vital signs
- Brain matter exposed or penetrating brain injury (GSW)
- Isolated drowning or hanging victims
- Objection to study voiced by subject or family member at the scene
- Inability to obtain IV or intraosseous access
- Isolated burns without evidence of traumatic injury
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Whole Blood
Subjects will receive up to two units of whole blood as collected by local blood bank procedures and stored at 1-6 degrees Celsius initiated in the prehospital phase of care. |
low titer whole blood, group O kept to either 21 days or 35 days based upon which preservation process is employed at each respective participating site |
|
Actieve vergelijker: Component transfusion
Subjects will receive prehospital crystalloid infusion or blood component transfusion resuscitation per site standard care for the respective Emergency Medical unit/service. |
crystalloid infusion or blood component transfusion resuscitation |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
30 Day Mortality
Tijdsspanne: thru 30 days of enrollment
|
All cause mortality within 30 days |
thru 30 days of enrollment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
3-hour Mortality
Tijdsspanne: Enrollment through 3 hours
|
Death within 3 hours of enrollment |
Enrollment through 3 hours
|
|
6-hour Mortality
Tijdsspanne: Enrollment through 6 hours
|
Death within 6 hours of enrollment |
Enrollment through 6 hours
|
|
24-hour Mortality
Tijdsspanne: Enrollment through 24 hours
|
Death within 24 hours of enrollment |
Enrollment through 24 hours
|
|
In-hospital Mortality
Tijdsspanne: Enrollment through hospital discharge or 30 days
|
Death prior to hospital discharge |
Enrollment through hospital discharge or 30 days
|
|
Blood and Blood Component Transfusion Amount
Tijdsspanne: Enrollment through 24 hours
|
Number of units of blood or blood component transfused |
Enrollment through 24 hours
|
|
Multiple Organ Failure (MOF)
Tijdsspanne: Enrollment through 7 days or ICU discharge
|
Organ dysfunction will be evaluated via the Denver Post-injury Multiple Organ Failure Score. Patients who are never admitted to the Intensive Care Unit (ICU) or those with a length of ICU stay of less than 48 hours will be considered to have a Denver score of 0. A summary of the Denver score may be calculated by summing the worst scores of each of the individual systems over the course of the ICU stay. A summary Denver score > 3 will be classified as MOF. |
Enrollment through 7 days or ICU discharge
|
|
Hospital-acquired Pneumonia
Tijdsspanne: Number of participants who develop pneumonia through 30 days
|
Pneumonia acquired during hospitalization per Center for Disease Control (CDC) criteria |
Number of participants who develop pneumonia through 30 days
|
|
Blood Stream Infection
Tijdsspanne: Number of participants who develop blood stream infection through 30 days
|
Blood stream infection during hospitalization per CDC criteria |
Number of participants who develop blood stream infection through 30 days
|
|
Acute Respiratory Distress Syndrome (ARDS)
Tijdsspanne: Number of participants who develop ARDS through 30 days
|
The Berlin definition for mild ARDS (PaO2/FIO2, ≤ 300 mm Hg + timing, imaging and origin criteria) will be utilized as a threshold value to determine the incidence of ARDS and will be further stratified into Moderate (PaO2/FIO2, ≤ 200 mm Hg) and Severe (PaO2/FIO2, ≤ 100 mm Hg). |
Number of participants who develop ARDS through 30 days
|
|
Abnormal International Normalized Ratio (INR)
Tijdsspanne: Enrollment through 60 minutes
|
Measurement of platelet hemostatic function |
Enrollment through 60 minutes
|
|
Achievement of Hemostasis
Tijdsspanne: Enrollment through 4 hours
|
Ability to reach nadir transfusion requirement of 1 unit of red blood cells in a 60-minute time period in the first 4 hours following arrival |
Enrollment through 4 hours
|
|
Transfusion Reaction
Tijdsspanne: Enrollment through 24 hours
|
Any transfusion complication |
Enrollment through 24 hours
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Jason L Sperry, MD, University of Pittsburgh
Publicaties en nuttige links
Algemene publicaties
- Brunskill SJ, Disegna A, Wong H, Fabes J, Desborough MJ, Doree C, Davenport R, Curry N, Stanworth SJ. Blood transfusion strategies for major bleeding in trauma. Cochrane Database Syst Rev. 2025 Apr 24;4(4):CD012635. doi: 10.1002/14651858.CD012635.pub2.
- Meizoso JP, Cotton BA, Lawless RA, Kodadek LM, Lynde JM, Russell N, Gaspich J, Maung A, Anderson C, Reynolds JM, Haines KL, Kasotakis G, Freeman JJ. Whole blood resuscitation for injured patients requiring transfusion: A systematic review, meta-analysis, and practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2024 Sep 1;97(3):460-470. doi: 10.1097/TA.0000000000004327. Epub 2024 Mar 27.
- Sperry JL, Guyette FX, Cotton BA, Luther JF, Utarnachitt RB, Kutcher ME, Daley BJ, Peetz AB, Patel MB, Goodman MD, Claridge JA, Patel N, Harbrecht BG, Hashmi ZG, Zarychanski R, Neal MD, Yazer MH, Martin-Gill C, Vincent LE, Harner AM, Meyer DE, Latimer AJ, Robinson BR, McKnight CL, Hinckley WR, Miller KR, Jansen JO, Martin D, Fox EE, Rosario-Rivera BL, Wisniewski SR; TOWAR Study Group. Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage. N Engl J Med. 2026 Jun 18;394(23):2317-2328. doi: 10.1056/NEJMoa2602167. Epub 2026 May 18.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- STUDY20110430
- W81XWH-16-D-0024 (Ander subsidie-/financieringsnummer: Department of Defense)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified data may be shared with the funding agency as well as other researchers upon request to the Principal Investigator.
IPD-tijdsbestek voor delen
Data will become available after publication of the primary manuscript.
IPD-toegangscriteria voor delen
Requests for data will be submitted in writing and reviewed by the Principal Investigator.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .